颈动脉夹层卒中预防的抗血栓治疗:STOP-CAD研究
这项多中心观察性回顾性国际研究纳入3636例颈动脉夹层患者,比较抗凝与抗血小板治疗。调整后抗凝与30天和180天缺血性卒中风险降低无显著相关,但180天严重出血风险显著升高;闭塞性夹层患者抗凝与缺血性卒中风险显著降低相关。
要点
- 抗凝与抗血小板相比,30天和180天缺血性卒中风险无显著差异。
- 抗凝治疗180天严重出血风险显著高于抗血小板(调整HR 5.56)。
- 闭塞性夹层患者抗凝与缺血性卒中风险显著降低相关。
核心结论
- 研究不能排除抗凝降低缺血性卒中风险的获益,尤其在闭塞性夹层患者中。
- 若选择抗凝,在180天前转为抗血小板治疗以降低严重出血风险似乎是合理的。
- 需要大型前瞻性研究验证这些发现。
研究设计与样本
- 多中心观察性回顾性国际研究,覆盖16个国家63个中心。
- 纳入无重大创伤的颈动脉夹层患者3636例。
- 暴露为抗血栓治疗类型(抗凝 vs 抗血小板),主要分析采用按治疗交叉方法。
- 使用调整Cox回归与逆概率治疗加权分析30天和180天内的结局。
主要发现
- 402例(11.1%)仅接受抗凝治疗,2453例(67.5%)仅接受抗血小板治疗。
- 至180天,162例(4.4%)发生新发缺血性卒中,28例(0.8%)发生严重出血;87.0%的缺血性卒中发生在30天内。
- 抗凝 vs 抗血小板:30天缺血性卒中调整HR 0.71(95%CI 0.45-1.12;P=0.145),180天调整HR 0.80(95%CI 0.28-2.24;P=0.670)。
- 抗凝 vs 抗血小板:30天严重出血调整HR 1.39(95%CI 0.35-5.45;P=0.637),180天调整HR 5.56(95%CI 1.53-20.13;P=0.009)。
- 交互分析中,闭塞性夹层患者抗凝与缺血性卒中风险显著降低相关(调整HR 0.40;95%CI 0.18-0.88;交互作用P=0.009)。
关键数值与推荐
- 抗凝 vs 抗血小板30天缺血性卒中调整HR 0.71(95%CI 0.45-1.12;P=0.145),无显著差异。
- 抗凝 vs 抗血小板180天缺血性卒中调整HR 0.80(95%CI 0.28-2.24;P=0.670),无显著差异。
- 抗凝 vs 抗血小板30天严重出血调整HR 1.39(95%CI 0.35-5.45;P=0.637),无显著差异。
- 抗凝 vs 抗血小板180天严重出血调整HR 5.56(95%CI 1.53-20.13;P=0.009),显著升高。
- 闭塞性夹层患者抗凝 vs 抗血小板缺血性卒中调整HR 0.40(95%CI 0.18-0.88;交互作用P=0.009),显著降低。
临床怎么用
- 若选择抗凝治疗,作者认为在180天前转为抗血小板治疗以降低严重出血风险似乎是合理的。
- 对于闭塞性夹层患者,作者指出研究不能排除抗凝降低缺血性卒中风险的获益。
- 原文未据此给出其他推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Small, randomized trials of patients with cervical artery dissection showed conflicting results regarding optimal stroke prevention strategies. We aimed to compare outcomes in patients with cervical artery dissection treated with antiplatelets versus anticoagulation. METHODS: This is a multicenter observational retrospective international study (16 countries, 63 sites) that included patients with cervical artery dissection without major trauma. The exposure was antithrombotic treatment type (anticoagulation versus antiplatelets), and outcomes were subsequent ischemic stroke and major hemorrhage (intracranial or extracranial hemorrhage). We used adjusted Cox regression with inverse probability of treatment weighting to determine associations between anticoagulation and study outcomes within 30 and 180 days. The main analysis used an as-treated crossover approach and only included outcomes occurring with the above treatments. RESULTS: The study included 3636 patients (402 [11.1%] received exclusively anticoagulation and 2453 [67.5%] received exclusively antiplatelets). By day 180, there were 162 new ischemic strokes (4.4%) and 28 major hemorrhages (0.8%); 87.0% of ischemic strokes occurred by day 30. In adjusted Cox regression with inverse probability of treatment weighting, compared with antiplatelet therapy, anticoagulation was associated with a nonsignificantly lower risk of subsequent ischemic stroke by day 30 (adjusted hazard ratio [HR], 0.71 [95% CI, 0.45-1.12]; P=0.145) and by day 180 (adjusted HR, 0.80 [95% CI, 0.28-2.24]; P=0.670). Anticoagulation therapy was not associated with a higher risk of major hemorrhage by day 30 (adjusted HR, 1.39 [95% CI, 0.35-5.45]; P=0.637) but was by day 180 (adjusted HR, 5.56 [95% CI, 1.53-20.13]; P=0.009). In interaction analyses, patients with occlusive dissection had significantly lower ischemic stroke risk with anticoagulation (adjusted HR, 0.40 [95% CI, 0.18-0.88]; Pinteraction=0.009). CONCLUSIONS: Our study does not rule out the benefit of anticoagulation in reducing ischemic stroke risk, particularly in patients with occlusive dissection. If anticoagulation is chosen, it seems reasonable to switch to antiplatelet therapy before 180 days to lower the risk of major bleeding. Large prospective studies are needed to validate our findings.
引用
- Yaghi S, Shu L, Mandel D, et al. Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection: The STOP-CAD Study. Stroke. 2024. PMID: 38335240. doi:10.1161/STROKEAHA.123.045731
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。